Risk Factors and Prognosis of Hepatic cGVHD after Allogeneic Hematopoietic Stem Cell Transplantation.
- Author:
Di YU
1
;
Ya-Hui HAN
1
;
Chen-Yuan HU
1
;
Bin ZHANG
1
;
Huan-Xin ZHANG
1
;
Hu-Jun LI
1
;
Kun-Ming QI
1
;
Jiang CAO
1
;
Zhen-Yu LI
1
;
Zhi-Ling YAN
2
;
Kai-Lin XU
3
Author Information
- Publication Type:Journal Article
- MeSH: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning
- From: Journal of Experimental Hematology 2018;26(4):1174-1179
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the risk factors and prognosis of hepatic chronic GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSThe clinical data of 147 patients undergoing allo-HSCT from January 2013 to December 2016 were analyzed, the correlation between recipient age and sex, disease state, matched degree of HLA, donor sex, stem cell sources, ATG in GVHD prophylaxis, liver dysfunction during conditioning period, pre-transplant HBsAg, prior aGVHD and hepatic cGVHD were studied, and the correlation between hepatic cGVHD and prognosis were analysed.
RESULTSThirty-two patients had hepatic cGVHD, cumulative incidence of 26.4%. In univariate analysis, pre-transplant HBsAgand liver dysfunction during conditioning period were not significantly related with hepatic cGVHD (P>0.05). In multivariate analysis, prior acute GVHD (HR=2.087, P=0.045) was the independent risk factor for hepatic cGVHD, ATG (HR=0.231, P=0.000) was significantly related with a lower incidence of hepatic cGVHD. In univariate analysis, patients with hepatic cGVHD had a lower 2 years relapse rate (P=0.038).
CONCLUSIONPrior acute GVHD is the independent risk factor for hepatic cGVHD, the ATG can significantly reduce the incidence of hepatic cGVHD. Hepatic cGVHD has been found to relate with a lower 2 years relapse rate.